Press Release

Asia-Pacific Human Insulin Market to Prosper Amidst Surging Prevalence of Diabetes

The Asia-Pacific Human Insulin Market is projected to grow at a CAGR of 8.12% during the forecast period of 2024-30, cites MarkNtel Advisors in the recent research report. The increasing urbanization, sedentary lifestyles, poor dietary choices, and a progressively aging demographic all contribute to the escalating prevalence of diabetes throughout various countries in the region. With diabetes incidence on the rise, there emerges an urgent demand for diabetes management solutions that are both readily available and cost-effective, particularly human insulin therapy.

Furthermore, the demand for human insulin has seen a notable boost in recent years, largely driven by the growing prevalence of gestational diabetes among pregnant women. Gestational diabetes mellitus (GDM) refers to elevated blood sugar levels during pregnancy, typically resolving postpartum. Throughout pregnancy, the placenta produces hormones that interfere with the body's insulin function, a natural phenomenon known as insulin resistance. Consequently, as the incidence of gestational diabetes rises across the region, there is a corresponding uptick in the demand for human insulin in the forthcoming years.

Moreover, increasing government initiatives are propelling the expansion and modernization of healthcare infrastructure to address the escalating demand for diabetes care. This encompasses the establishment of specialized diabetes clinics, endocrinology departments, and diabetes centers across the region. Hence, the expansion of healthcare infrastructure is facilitating improved accessibility to human insulin therapy for individuals with diabetes in the upcoming years, further states the research report, “Asia-Pacific Human Insulin Market Analysis, 2024.”

Asia-Pacific Human Insulin Market Segmentation Analysis

Hospitals/Clinics Would Hold Major Market Share

Based on the end-user segment, the market is further bifurcated into Hospitals/Clinics, Home/Personal. Among them, the Hospitals/Clinics segment is expected to retain a significant share of the APAC Human Insulin Market in the forthcoming period. Hospitals/clinics play a key role as primary hubs for addressing the diagnosis, treatment, and ongoing management of diabetes. They offer comprehensive care services tailored to the specific needs of diabetic patients, encompassing various aspects such as access to human insulin therapy, medical consultations, diagnostic assessments, medication oversight, and educational programs focused on diabetes management.

Moreover, these medical centers are equipped with advanced treatment options & technologies designed to enhance diabetes care. The integration of these technologies into diabetes management practices not only improves treatment efficacy and patient outcomes but also enhances convenience and satisfaction among patients.

China is Anticipated to Account for Prominent Share of the APAC Human Insulin Market

The growing elderly population and the escalating prevalence of diabetes in China have fueled a surge in domestic consumption of human insulin in recent years. As individuals age, their susceptibility to developing type 2 diabetes rises due to factors like reduced physical activity, metabolic changes, and other age-related health issues. According to the World Health Organization (WHO), China has one of the fastest-growing aging populations globally, with a substantial number of individuals aged 60 and above. With this aging trend in China, there's a corresponding uptick in diabetes cases among the elderly population, leading to heightened demand for insulin in the nation.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market players, including Becton, Dickinson and Company (BD), Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Wockhardt Limited, Lupin Limited, Novo Nordisk A/S, Eris Lifesciences, Sanofi, Tonghua Dongbao Pharmaceutical Co., Ltd, and others, are looking forward to strengthening their market position.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the Asia-Pacific Human Insulin Market?
3. What key factors would propel and impede the industry across the country?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition been shaping across various countries?
6. How has the buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2019-2030?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?